Related Experiment Video
Updated: Jun 5, 2025
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Outcomes From a
Mukurdipi Ray1, Bhawani Pathak1, Ravi Venugopal1
1Surgical Oncology, All India Institute of Medical Sciences, New Delhi, Delhi, IND.
Background:
Malignant peritoneal mesothelioma (MPM) is a rare and aggressive form of cancer arising from the peritoneum. The prognosis for MPM has historically been poor, and treatment options are limited. This study evaluated the impact of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) as a treatment modality for MPM.
Materials And Methods:
This retrospective analysis included 15 patients diagnosed with MPM between 2012 and 2023 at a tertiary referral cancer care center in North India. Patients underwent CRS followed by HIPEC. The study assessed outcomes based on overall survival (OS) and postoperative morbidity rates.
Results:
Demographic analysis revealed a female preponderance (n = 9, 60%) and a majority of younger patients, 80% (n = 12) of whom were younger than the age of 50. The mean peritoneal cancer index (PCI) was 14.0, with 60% (n = 9) of patients having a PCI above the mean. The completeness of cytoreduction (CC) varied, with 40% (n = 6) achieving CC0, 33.33% (n = 5) CC1, and 26.67% (n = 4) CC2. Adjuvant chemotherapy was administered to 60% (n = 9) of the patients. The median follow-up period was 25 months, revealing an overall median survival of 27.0 months, with one- and three-year survival rates of 86.7% and 33.3%, respectively.
Conclusion:
CRS combined with HIPEC is a viable and effective treatment option for patients with MPM and offers improved survival rates and an acceptable safety profile. These findings support the integration of this treatment modality into the management plan for select patients with MPM, although optimal management is still evolving.
Insights
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) offers improved survival for malignant peritoneal mesothelioma (MPM). This treatment approach demonstrated a median survival of 27 months in a North Indian cohort.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Malignant peritoneal mesothelioma (MPM) is a rare and aggressive cancer with limited treatment options.
- The prognosis for MPM has historically been poor.
- This study investigated cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for MPM treatment.
Purpose of the Study:
- To evaluate the impact of CRS combined with HIPEC on overall survival (OS) in MPM patients.
- To assess postoperative morbidity rates associated with this combined treatment modality.
- To determine the efficacy of CRS + HIPEC for MPM management.
Main Methods:
- Retrospective analysis of 15 MPM patients treated between 2012 and 2023.
- Patients underwent CRS followed by HIPEC.
- Outcomes were assessed based on OS and postoperative morbidity.
Main Results:
- Median overall survival was 27.0 months.
- One- and three-year survival rates were 86.7% and 33.3%, respectively.
- The study included a majority of younger patients (80% < 50 years) and female preponderance (60%).
Conclusions:
- CRS combined with HIPEC is a viable and effective treatment for MPM.
- This modality offers improved survival rates and an acceptable safety profile.
- Findings support integrating CRS + HIPEC into MPM management for select patients.
